NICE has been unable to recommend imatinib (Glivec) as an adjuvant treatment for people who have had a gastrointestinal stromal tumour (GIST) removed and who are at risk of the cancer recurringThere is evidence to show that giving imatinib after surgery, as adjuvant therapy, can delay the recurren

read more>>

In draft guidance published today NICE has recommended two treatments for multiple myelomaThalidomide (Thalidomide, Celgene) in combination with an alkylating agent and a corticosteroid is recommended for the first-line treatment of multiple myeloma in people for whom high-dose chemotherapy with s

read more>>

Leiden, The Netherlands -- Biotech company Pharming Group NV (“Pharming” or “the Company”) (NYSE Euronext: PHARM) today announced that it intends to submit the Biologic License Application (BLA) to the US Food and Drug Administration (FDA) to obtain marketing approval for F

read more>>

COLUMBIA, Md. -- Celsion Corporation (Nasdaq: CLSN), a leading oncology drug development company, today announced that the U.S. Food and Drug Administration (FDA) has designated the HEAT Study of its investigational drug, ThermoDox(R), in combination with radiofrequency ablation (RFA), as a Fast T

read more>>

Use of an experimental targeted drug to treat metastatic melanoma tumors with a specific genetic signature was successful in more than 80 percent of patients in a phase 1 clinical trialResults of the trial of PLX4032, an inhibitor of a protein called BRAF that is overactive in more than half of al

read more>>

An experimental malaria drug developed by Ranbaxy Laboratories Ltd. was effective and safe in a mid-stage clinical trial, according to a study that suggests the treatment may offer an alternative to current medicinesAmong 230 people with the deadliest form of malaria in Thailand, India and Tanzani

read more>>

SOUTH SAN FRANCISCO, Calif. -- Actelion Pharmaceuticals US, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved the brand name VELETRI® for the company's epoprostenol for injection therapyVELETRI has been commercially available since April 2010 as Epoprostenol

read more>>

Although a new surge of scientific research has uncovered telltale signs of Alzheimer's disease that show up in brain scans and spinal taps, many questions remain unanswered about the clinical value of early testing and the overall direction of patient care, according to Dr. Kenneth S. Kosik, Kosi

read more>>

Clinuvel Pharmaceuticals Limited today announced that it will begin a pilot trial (CUV031) with its first-in-class drug SCENESSE® (afamelanotide) as a repigmentation therapy in the pigmentary disorder vitiligo. The trial will focus on patients diagnosed with nonsegmental vitiligo (NSV), the Du

read more>>

NES-ZIONA, Israel -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), a company developing next generation biobetter therapeutic proteins, today announced that it has received regulatory clearance from the U.S. Food and Drug Administration (FDA) to conduct a Phase II clinical trial in the U.S. of its The

read more>>